Profusa, a company that is developing connected tissue-implanted biosensors, has raised just over $45 million in Series C funding. Participants in the round included new investors VMS Investment Group, Tasly Pharmaceutical Group, and Maxim Integrated, as well as returning backers 3E Bioventures Capital and Atinum Investment.
The company will be using the new financing to bring its CE Marked sensor, the Profusa Lumee Oxygen Platform, toward commercialization and continue development of another continuous biosensor focused on glucose detection.
This morning, Sansoro Health, a healthcare integration company focused on interoperability, announced that it has raised $8 million in Series B funding, bringing the company’s total financing to $14.5 million. This round was led by LRVHealth with participation from existing investors Bain Capital Ventures and Healthy Ventures.
Instant Blood Pressure, an app from Aura Labs, has been removed from the app store for more than two years.
Online pharmacy and delivery service Capsule has landed a whopping $50 million in Series B funding led by Thrive Capital and Brook Capital Partners. The company, which defines itself by its same-day delivery policy, is now looking to expand its New York-based business to a national market.
Alder Hey Children’s Hospital and NHS Foundation Trust will be rolling out HoloLens mixed reality headsets to support its operational theater, according to a recent release from Microsoft.
Alongside the technology company and Black Marble, a software design and consultancy firm, the hospital will be developing an app for the technology to help surgeons better access information about their patients during an ongoing procedure.
The astronauts currently on the International Space Station rely on telemedicine for everything from coughs to bruises. But as Dr. Shannan Moynihan, deputy chief of space and occupational medicine at the NASA Johnson Space Center, said in a presentation at HIMSS18, telemedicine has its limits for caring for astronauts.
Bankrupting docs? Patient booking platform Zocdoc is putting providers in a sticky situation, CNBC reports. The platform, which lets patients book and cancel appointments, is changing its business model. Now instead of charging providers a flat annual rate per doctor, it proposes to charge a lower annual rate as well as a booking fee for each new customer.
The FDA announced today that it will allow marketing of Natural Cycles’ contraception app in the US for pre-menopausal women aged 18 years and older. Previously approved in the UK and currently the subject of investigation by multiple regulatory agencies, the algorithm-driven app helps users track their menstrual cycle and informs them when they are most fertile.
Shortly after launching its integrated continuous glucose monitoring system, Dexcom announced a 42 percent increase in year-over-year sales during its Q2 earnings call.
“Not only did we exceed our annual growth guidance for the second consecutive quarter but the business continues to accelerate,” Kevin Ronald Sayers, CEO of Dexcom, said during the call. “All of our key segments demonstrated strong year-over-year growth with US and [out of US] revenues up 35 percent and 78 percent, respectively.”